Sclerosing cholangitis

被引:10
作者
Björnsson, E
Chapman, RW
机构
[1] Sahlgrens Univ Hosp, Sect Gastroenterol & Hepatol, Dept Internal Med, SE-41345 Gothenburg, Sweden
[2] John Radcliffe Hosp, Dept Gastroenterol, Oxford OX3 9DU, England
关键词
D O I
10.1097/00001574-200305000-00011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by strictures and dilatations of the biliary tree. The median survival has been reported to be 12 years from diagnosis but patients diagnosed during the last decade have been shown to have longer survival of a median of 18 years. Small duct PSC seems to be an entity of its own and rarely progresses to large duct PSC and the prognosis of small duct PSC is much better than in large duct disease. Cholangiocarcinoma does not develop in patients with small duct PSC according to recently published studies. Autoantibodies binding to biliary epithelial cells have been demonstrated in sera from patients with PSC but the pathogenic role of these remains to be determined. It is suggested that inflammatory bowel disease is accelerated after orthotopic liver transplantation. MR cholangiopancreatography is increasingly used in clinical practice and has been reported to have similar diagnostic accuracy as ERCP. However, lack of standardization of this novel technology makes it unclear if it can supersede ERCP as a diagnostic tool in PSC at the present time. Better diagnostic tests to detect cholangiocarcinoma in patients with PSC are urgently needed. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 33 条
[1]   Clinical profile of primary sclerosing cholangitis in Singapore [J].
Ang, TL ;
Fock, KM ;
Ng, TM ;
Teo, EK ;
Chua, TS ;
Tan, JYL .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (08) :908-913
[2]   Pirfenidone in the treatment of primary sclerosing cholangitis [J].
Angulo, P ;
MacCarty, RL ;
Sylvestre, PB ;
Jorgensen, RA ;
Wiesner, RH ;
LaRusso, NA ;
Lindor, KD .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) :157-161
[3]   Small-duct primary sclerosing cholangitis: A long-term follow-up study [J].
Angulo, P ;
Maor-Kendler, Y ;
Lindor, KD .
HEPATOLOGY, 2002, 35 (06) :1494-1500
[4]   Hepatic and extrahepatic malignancies in primary sclerosing cholangitis [J].
Bergquist, A ;
Ekbom, A ;
Olsson, R ;
Kornfeldt, D ;
Lööf, L ;
Danielsson, Å ;
Hultcrantz, R ;
Lindgren, S ;
Prytz, H ;
Sandberg-Gertzén, H ;
Almer, S ;
Granath, F ;
Broomé, U .
JOURNAL OF HEPATOLOGY, 2002, 36 (03) :321-327
[5]  
BJOMSSON E, 2002, GUT, V51, P731
[6]  
BJORNSSON E, 2002, MOL PATHOGENESIS CHO
[7]  
Blendis Laurence, 2002, Gastroenterology, V123, P647
[8]   Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis [J].
Boberg, KM ;
Rocca, G ;
Egeland, T ;
Bergquist, A ;
Broomé, U ;
Caballeria, L ;
Chapman, R ;
Hultcrantz, R ;
Mitchell, S ;
Pares, A ;
Rosina, F ;
Schrumpf, E .
HEPATOLOGY, 2002, 35 (03) :652-657
[9]   Cholangiocarcinoma in primary sclerosing cholangitis:: Risk factors and clinical presentation [J].
Boberg, KM ;
Bergquist, A ;
Mitchell, S ;
Pares, A ;
Rosina, F ;
Broomé, U ;
Chapman, R ;
Fausa, O ;
Egeland, T ;
Rocca, G ;
Schrumpf, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (10) :1205-1211
[10]   Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC) [J].
Broomé, U ;
Glaumann, H ;
Lindström, E ;
Lööf, L ;
Almer, S ;
Prytz, H ;
Sandberg-Gertzén, H ;
Lindgren, S ;
Fork, FT ;
Järnerot, G ;
Olsson, R .
JOURNAL OF HEPATOLOGY, 2002, 36 (05) :586-589